Literature DB >> 29476954

Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.

.   

Abstract

In 2014, the National Institutes of Health sponsored the second Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (GVHD). The purpose was to update recommendations about key elements of chronic GVHD research, including definitions for diagnosis, severity scoring, and response measures, based on empirical data published since the first 2005 Consensus Conference. The most significant modifications were to the response assessments, based on studies demonstrating difficulty with the first consensus definitions. The Response Measures Validation Study is a multicenter, prospective cohort study of patients who are starting initial or subsequent treatments for chronic GVHD. The aim of the study is to evaluate the performance of the 2014 response measures and determine whether any other combination of assessments is superior. Clinical data, clinician assessments, patient-reported outcomes, and research samples are collected at enrollment and 3, 6, and 18 months later, and whenever another chronic GVHD systemic treatment is added. The target enrollment of 368 evaluable patients from 12 transplantation centers has been reached. This report describes the rationale, design, and methods of the Chronic GVHD Response Measures Validation Study, and invites other investigators to collaborate with the Consortium to analyze data or specimens.
Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; Biorepository; Chronic graft-versus-host disease; Prospective longitudinal observational study; Response assessment

Mesh:

Year:  2018        PMID: 29476954      PMCID: PMC6103904          DOI: 10.1016/j.bbmt.2018.02.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  19 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

2.  Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.

Authors:  John M Goldman; Navneet S Majhail; John P Klein; Zhiwei Wang; Kathleen A Sobocinski; Mukta Arora; Mary M Horowitz; J Douglas Rizzo
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-19       Impact factor: 5.742

4.  Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.

Authors:  G Socié; J V Stone; J R Wingard; D Weisdorf; P J Henslee-Downey; C Bredeson; J Y Cahn; J R Passweg; P A Rowlings; H C Schouten; H J Kolb; J P Klein
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

5.  Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.

Authors:  Joseph Pidala; Brenda F Kurland; Xiaoyu Chai; Georgia Vogelsang; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; Navneet Majhail; Stephanie J Lee
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

6.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

7.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

8.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.

Authors:  Stephanie k Lee; E Francis Cook; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

9.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

10.  Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.

Authors:  Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

View more
  6 in total

1.  Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Paul J Martin; Stephanie J Lee; Amin A Momin; Laura Tabellini; Lynn E Onstad; Joseph Pidala; Mary E D Flowers; Richard L Lawler; Hiroyuki Katayama; Samir Hanash; John A Hansen
Journal:  Blood Adv       Date:  2020-06-09

2.  Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.

Authors:  Paul J Martin; Barry E Storer; Jeanne Palmer; Madan H Jagasia; George L Chen; Raewyn Broady; Mukta Arora; Joseph A Pidala; Betty K Hamilton; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-11       Impact factor: 5.742

3.  Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale.

Authors:  Christopher Teh; Lynn Onstad; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-20       Impact factor: 5.742

4.  Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia.

Authors:  Yoshihiro Inamoto; Stephanie J Lee; Lynn E Onstad; Mary E D Flowers; Betty K Hamilton; Madan H Jagasia; Paul J Martin; Steven Z Pavletic; Joseph A Pidala; Iskra Pusic; Georgia B Vogelsang; Daniel Wolff; Paul A Carpenter
Journal:  Blood Adv       Date:  2020-01-14

5.  Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Yoshihiro Inamoto; Paul J Martin; Lynn E Onstad; Guang-Shing Cheng; Kirsten M Williams; Iskra Pusic; Vincent T Ho; Mukta Arora; Joseph Pidala; Mary E D Flowers; Ted A Gooley; Richard L Lawler; John A Hansen; Stephanie J Lee
Journal:  Transplant Cell Ther       Date:  2021-06-12

6.  Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.

Authors:  Zachariah DeFilipp; Amin M Alousi; Joseph A Pidala; Paul A Carpenter; Lynn E Onstad; Sally Arai; Mukta Arora; Corey S Cutler; Mary E D Flowers; Carrie L Kitko; George L Chen; Stephanie J Lee; Betty K Hamilton
Journal:  Blood Adv       Date:  2021-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.